2Q FY23 highlights (vs 2Q FY22):Operating revenue up 89.9% to...

2Q FY23 highlights (vs 2Q FY22):

• Operating revenue up 89.9% to $44.1 million

  • ○ US up 97.7% to $39.4 million, underpinned by expansion of the COVID-19 awareness program combined with increased pharmacy participation in the US digital platform, inMotion

  • ○ Australia up 42.6% to $4.7 million, including three-month contribution from GuildLink of $1.3 million; excluding GuildLink underlying revenue was up 2.8%

• Gross margin up 164.3% to $26.4 million, with an increase of 16.9 ppts (59.9% vs 43.1%)

• Strong capital position, with $32.7 million cash on 31 December 2022, an increase of

  $20.8 million cash for the quarter

• Kevin Hutchinson, US health tech executive, appointed as non-executive director (US based)

• Expansion of US digital platform network (inMotion) via a pharmacy software group representing circa 10,000 pharmacies

• COVID-19 awareness program in the US extended to end of 2022

• Two-year pathway to profitability strategy presented at 2022 AGM

• 1H FY23 operating revenue of $64.1 million1, up 65.8% on 1H FY22 ($38.7 million)